Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 20, 2007
Event: Entry into a Material Definitive Agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement regarding drug procurement.
Material Changes and Agreement Details
On December 20, 2007, DaVita Inc. entered into a new Dialysis Organization Agreement with Amgen USA Inc. to purchase Epoetin alfa (Epogen), a drug used in the treatment of dialysis patients. Key terms include:
- Supplier: Amgen is the sole supplier of Epogen.
- Term: January 1, 2008, to December 31, 2010.
- Pricing: The agreement provides for discount pricing and rebates.
- Rebate Conditions: Some rebates are subject to qualification requirements based on process improvement targets and data submission.
- Termination: Either party may terminate with prior written notice.
- Modification: Terms may be modified or renegotiated in the event of a change in law or regulation.
This agreement replaces the prior agreement effective February 3, 2006, which expired on December 31, 2007.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or management commentary on future performance. The primary contingency noted is that rebate eligibility depends on meeting specific qualification requirements during the agreement term. Additionally, the agreement is subject to modification if laws or regulations change.
Investor Verification Checklist
- Verify the specific discount rates and rebate percentages detailed in the full agreement text.
- Confirm the specific process improvement targets and data submission requirements necessary to qualify for rebates.
- Assess the impact of the new pricing structure on DaVita's cost of goods sold compared to the expiring 2006 agreement.
- Monitor for any regulatory changes that could trigger a renegotiation of the agreement terms.